"In particular, the hepatitis B program is attracting considerable interest from pharmaceutical companies. Based on this interest and anticipated in vivo data, combined with a significant potential market opportunity, Benitec will now prioritise the hepatitis B program as its next candidate for clinical development."
It sucks, but from a commercialization standpoint, this is probably a wise decision. Hep B still needs a cure, and with the data in hand, hopefully Benitrc will be on par with those in the Hep B arena, instead of a step behind. Heck, they could hopefully start with larger doses, and have cure rates in earlier cohorts!
BLT Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
